Skip to main content
SpringerLink
Log in

The effect of two different doses of oral clodronate on pain in patients with bone metastases

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the efficacy of low dose oral clodronate in palliation of pain arising from bone metastases (BM) and to determine the optimal oral clodronate dose which inhibits osteolysis caused by tumor. Fifty patients with bone pain caused by BM were included in this study. All were receiving antitumor chemotherapy or hormonal therapy. The patients were randomized into three groups according to the dose of clodronate. Groups A and B were given 800 mg/d and 1600 mg/d of oral clodronate respectively for 3 months. Group C was the control group. The effect of clodronate in pain palliation was evaluated with pain score, performance status, and changes in analgesic use. The effect on osteolysis was examined with urinary calcium, hydroxyproline (OHP) and serum cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) levels. Group A contained 16 patients, and groups B and C contained 17 patients each. After 3 months use of oral clodronate, significant decrease in the pain score of groups A and B was noted when, compared to group C (P=0.024 andP=0.007, respectively) The analgesic use of 11 patients in group A (69%) and 8 patients in group B (47%) was decreased, but only the decrease in group A was statistically significant (P=0.038). Pain score increased in 5 patients in group C (29%), and 3 patients in groups A (19%) and B (18%) each. Urinary calcium, OHP and serum ICTP levels increased in group C and decreased in groups A and B, but only the decrease of urinary calcium levels of group B was significant (P=0.003). In conclusion, low dose (800 mg/d) oral clodronate seems to be as effective as standard dose (1600 mg/d) in palliation of bone pain secondary to BM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hanks GW. The pharmacological treatment of bone pain.Cancer Surv 1988;7: 87–101.

    CAS  PubMed  Google Scholar 

  2. Fleisch H. Biphosphonates—history and experimental basis.Bone 1987;8 (Suppl 1): S23-S28.

    CAS  PubMed  Google Scholar 

  3. Fleisch Het al. Structure activity relationship of various biphosphonates.Calcif Tissue Int 1983;35: 87–99.

    Article  PubMed  Google Scholar 

  4. Preston CJet al. Effective short term treatment of Paget’s disease with oral etidronate.Br Med J 1986;292: 79–80.

    Article  CAS  Google Scholar 

  5. Yates AJPet al. Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone.Lancet 1985;1: 1474–1477.

    Article  CAS  PubMed  Google Scholar 

  6. McCloskey EVet al. Comparative effects of intravenous diphosphonate on calcium and skeletal metabolism in man.Bone 1987;8 (Suppl 1): S35-S41.

    PubMed  Google Scholar 

  7. van-Holten-Verzantvoort ATMet al. Palliative pamidronate treatment in patients with bone metastases from breast cancer.J Clin Oncol 1993;11: 491–498.

    Article  CAS  PubMed  Google Scholar 

  8. Paterson AHGet al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.J Clin Oncol 1993;11: 59–65.

    Article  CAS  PubMed  Google Scholar 

  9. Kanis AJ, O’Rourke N, McCloskey EV. Consequences of neoplasia induced bone resorption and the use of clodronate.Int J Oncol 1994;5: 713–731.

    CAS  PubMed  Google Scholar 

  10. Adami S, Main M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma.Cancer Res 1994;116: 67–72.

    Google Scholar 

  11. Siris ESet al. Effects of dichloromethylene diphosphonate on skeletal mobilisation of calcium in multiple myeloma.N Engl J Med 1980;302: 310–315.

    Article  CAS  PubMed  Google Scholar 

  12. Elomaa Iet al Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.Lancet 1983;1: 146–149.

    Article  CAS  PubMed  Google Scholar 

  13. Kymala Tet al. Evaluation of the effect of oral clodronate on the skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish prostate cancer group.Eur J Cancer 1993;29A: 821–825.

    Article  Google Scholar 

  14. Sriwantanakul Ket al. Studies with different types of visual analog scales for measurement of pain.Clin Pharmacol Ther 1983;34: 234–239.

    Article  Google Scholar 

  15. Dawson-Saunders B, Trapp RG.Basic & Clinical Biostatistics 2nd ed. Prentice-Hall International Inc. Connecticut, 1994.

    Google Scholar 

  16. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study.J Clin Oncol 1995;13: 2427–2430.

    Article  CAS  PubMed  Google Scholar 

  17. Ernst DS, McDonald RN, Paterson AHG, Jensen J, Bruera E. A double-blind, cross-over trial of IV clodronate in metastatic bone pain.J Pain Sympt Man 1992;7: 4–11.

    Article  CAS  Google Scholar 

  18. O’Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.J Clin Oncol 1995;13: 929–934.

    Article  PubMed  Google Scholar 

  19. Percival RCet al. Treatment of malignant hypercalcemia with clodronate.Br J Cancer 1985;51: 665–669.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Coombes RCet al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer.Cancer 1983;52: 610–614.

    Article  CAS  PubMed  Google Scholar 

  21. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is useful prognostic indicator in multiple myeloma.Br. J Cancer 1992;66: 337–341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radio-immunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation.Clin Chem 1993;39: 635–640.

    Article  CAS  PubMed  Google Scholar 

  23. Elomaa Iet al. Monitoring the action of clodronate with type I collagen metabolites in mutiple myeloma.Eur J Cancer 1996;32A: 1166–1170.

    Article  CAS  PubMed  Google Scholar 

  24. Elomaa I, Blomqvist C. Clodronate and other bisphosphonates as supportive therapy in osteolysis due to malignancy.Acta Oncol 1995;34: 629–636.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Ankara University, Faculty of Medicine, Ankara, Turkey

    F İçli, H Akbulut, O Şencan, M Samur, N Açikgöz & A Demirkazik

  2. Department of Internal Medicine, Ankara University, Faculty of Medicine, Ankara, Turkey

    M Çakir

  3. Department of Medical Oncology, Baçskent University Faculty of Medicine, Fevzi Çakmak Bulvari 10, Sokak No: 45 06490, Bahçelievler, Ankara, Turkey

    A Arican

Authors
  1. A Arican
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F İçli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Akbulut
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Çakir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O Şencan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Samur
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Açikgöz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Demirkazik
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arican, A., İçli, F., Akbulut, H. et al. The effect of two different doses of oral clodronate on pain in patients with bone metastases. Med Oncol 16, 204–210 (1999). https://doi.org/10.1007/BF02906133

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02906133

Keywords

Search

Navigation